Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 8/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | LITAF | Q99732 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409501 | 0.82 | FEN1 (0.57) | PDE4BPDE4DFEN1ALDH1A1MAPT | |
| SCHEMBL2406659 | 0.81 | KMT2A (0.55) | PDE4BPDE4DFEN1KDM4EALDH1A1 | |
| SCHEMBL4194695 | 0.78 | PDE4B (0.47) | PDE4BPDE4DELANEKDM4EMAPT | |
| SCHEMBL5256357 | 0.78 | KDM4D (0.45) | PDE4BPDE4DELANEGRM5KDM4E | |
| SCHEMBL2412123 | 0.77 | PDE4A (0.57) | PDE4BPDE4DKDM4EALDH1A1MAPT | |
| SCHEMBL17463118 | 0.77 | PDE4B (0.47) | PDE4BPDE4DELANEGRM5KDM4E | |
| SCHEMBL4185632 | 0.76 | PDE4B (0.48) | PDE4BPDE4DNOTUMFEN1 | |
| SCHEMBL2409929 | 0.74 | PDE4B (0.42) | PDE4BPDE4DELANEFEN1ALDH1A1 | |
| SCHEMBL2407901 | 0.72 | PKM (0.52) | PDE4BKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL5251274 | 0.72 | PDE4A (0.67) | PDE4BPDE4DFEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| US-7608716-B2 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1559716-A1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | Grelan Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | PDE3B, PDE3A, PDE4A | PDE4B 4/4885PDE4D 11/4885ELANE 362/4885 |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | PDE4B 6/4885PDE4D 11/4885ELANE 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.